Insider buy: Cognition Therapeutics (CGTX) CMO adds 10,000 shares

Rhea-AI Filing Summary

Cognition Therapeutics Inc. Chief Medical Officer Anthony Caggiano reported an open-market purchase of 10,000 shares of the company’s Common Stock on April 16, 2026 at a price of $1.11 per share. Following this transaction, his direct holdings increased to 874,906 shares of Common Stock.

Insider Trade Summary

Net Buyer: 10,000 shares ($11,100)

Net Buy 1 txn

Insider Caggiano Anthony

Role Chief Medical Officer

Bought 10,000 shs ($11K)

Type	Security	Shares	Price	Value
Purchase	Common Stock	10,000	$1.11	$11K

Holdings After Transaction: Common Stock — 874,906 shares (Direct, null)

Footnotes (1)

Key Figures

Shares purchased: 10,000 shares Purchase price: $1.11 per share Shares held after transaction: 874,906 shares +1 more

4 metrics

Shares purchased 10,000 shares Open-market purchase on April 16, 2026

Purchase price $1.11 per share Price paid for Cognition Therapeutics Common Stock

Shares held after transaction 874,906 shares Direct Common Stock holdings after April 16, 2026 trade

Net buy shares 10,000 shares Net effect of reported Form 4 transactions

Key Terms

open-market purchase, Common Stock, Form 4, Chief Medical Officer

4 terms

open-market purchase financial

"reported an open-market purchase of 10,000 shares of the company’s Common Stock"

An open-market purchase is when an investor or a company buys shares on a public stock exchange at the going market price, rather than through a private deal. It matters to investors because these purchases change how many shares are available, can push the stock price up or signal confidence from large buyers, and often affect per-share metrics like earnings—think of it like someone buying lots of apples off a grocery shelf, reducing supply and potentially raising the price.

Common Stock financial

"10,000 shares of the company’s Common Stock on April 16, 2026"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

Form 4 regulatory

"according to a new Form 4 filing"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

Chief Medical Officer financial

"Chief Medical Officer Anthony Caggiano reported an open-market purchase"

A chief medical officer is a senior executive responsible for overseeing the health and medical strategies within an organization, often in the healthcare or pharmaceutical sectors. They play a key role in guiding decisions related to medical research, product safety, and healthcare policies, which can impact a company's reputation and success. For investors, understanding the chief medical officer's role helps gauge how well a company manages medical risks and advances its healthcare goals.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Caggiano Anthony

(Last) (First) (Middle)

C/O COGNITION THERAPEUTICS INC

2500 WESTCHESTER AVE.

(Street)

PURCHASE NEW YORK 10577

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
COGNITION THERAPEUTICS INC [ CGTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Medical Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/16/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	04/16/2026		P		10,000	A	$1.11	874,906	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/ Lisa Ricciardi, Attorney-in-Fact	04/20/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Cognition Therapeutics (CGTX) report on this Form 4?

The filing shows Chief Medical Officer Anthony Caggiano completed an open-market purchase of 10,000 shares of Cognition Therapeutics Common Stock at $1.11 per share, increasing his direct ownership stake in the company.

Who is the Cognition Therapeutics (CGTX) insider involved in this Form 4?

The insider is Anthony Caggiano, the Chief Medical Officer of Cognition Therapeutics. He reported buying 10,000 shares of Common Stock in an open-market transaction, bringing his directly held position to 874,906 shares after the purchase.

How many Cognition Therapeutics (CGTX) shares did Anthony Caggiano buy?

Anthony Caggiano bought 10,000 shares of Cognition Therapeutics Common Stock. The shares were acquired in an open-market transaction, and this trade increased his total directly held position to 874,906 shares according to the reported holdings.

At what price were the Cognition Therapeutics (CGTX) shares purchased in this insider trade?

The reported insider trade was executed at a price of $1.11 per share. Chief Medical Officer Anthony Caggiano acquired 10,000 shares of Cognition Therapeutics Common Stock at that price in an open-market purchase on April 16, 2026.

What are Anthony Caggiano’s Cognition Therapeutics (CGTX) holdings after this Form 4 transaction?

After the reported transaction, Anthony Caggiano directly holds 874,906 shares of Cognition Therapeutics Common Stock. This total reflects his position immediately following the open-market purchase of 10,000 additional shares disclosed in the Form 4.